U01 grant from National Institutes of Health (2016-2021), Development of EP2 Antagonists for the suppression of Alzheimer’s neuropathology.

R21/R33 grant from National Institutes of Health (2017-2020), EP2 antagonists as novel anti-epileptogenic agents.

Alzheimer’s Drug Discovery Foundation (ADDF) (2013-2016), EP2 antagonists for the suppression of inflammation and neuropathology in Alzheimer's model.

Harrington Discovery Foundation (2014-2016), Formulation studies of EP2 antagonists.